Description

This fund's primary objective is to achieve substantial capital appreciation over an extended period. To accomplish this, it typically commits a minimum of 80% of its total capital (including any funds borrowed for investment) to companies that its management team identifies as having a strong focus on life sciences. Furthermore, as a fundamental rule, the fund generally allocates at least 25% of its overall assets to businesses formally categorized within the broader "life sciences" sector.